Insiders Buying Superior Drilling Products And 2 Other Penny Stocks

The Dow Jones closed higher by over 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Superior Drilling Products

• The Trade: Superior Drilling Products Inc SDPI 10% owner Star Equity Holdings Inc bought a total of 79,837 shares at an average price of $0.97. To acquire these shares, it cost around $77.49 thousand.
• What’s Happening: Superior Drilling sees FY22 revenue of $19 million to $19.2 million.
• What Superior Drilling Products Does: Superior Drilling Products Inc is engaged in providing equipment and services to the oil and gas industry.

GlycoMimetics

• The Trade: GlycoMimetics Inc GLYC 10% owner Invus Public Equities Advisors, LLC acquired a total 400,000 shares at an average price of $1.78. The insider spent around $712.25 thousand to buy those shares.
• What’s Happening: GlycoMimetics announced since the start of Q4 2022, it sold 11,776,784 shares of common stock under its existing at-the-market sales facility, raising a total of $32.9 million in net proceeds.
• What GlycoMimetics Does: GlycoMimetics Inc is a clinical stage biotechnology company.

Check This Out: Top 5 Energy Stocks Which Could Rescue Your Portfolio This Month

VolitionRX

• The Trade: VolitionRX Ltd VNRX Director Guy Archibald Innes acquired a total of 234,000 shares at an average price of $1.75. To acquire these shares, it cost around $409.5 thousand.
• What’s Happening: VolitionRX announced pricing of a $4.3 million share common stock offering at $1.75 per share.
• What VolitionRX Does: VolitionRX Ltd is a us-based multi-national life sciences company. It is engaged in developing easy to use blood-based tests to accurately diagnose a range of cancers.

Don’t forget to check out our premarket coverage here